Vasogen cuts execs
This article was originally published in The Gray Sheet
Vasogen consolidates management April 11 to improve efficiencies and reduce costs. Chief Operating Officer Christopher Waddick reassumes the chief financial officer title, replacing Paul Van Damme. Waddick was Vasogen's CFO from 1997 until he became COO in 2005. Eldon Smith, VP-scientific affairs, takes over position from Jay Kleiman, who retires as chief medical officer and head of cardiovascular development. Vasogen, working to commercialize its Celacade immune modulation therapy for peripheral arterial disease and chronic heart failure, reported a loss of $6.75 million in the first quarter (ended Feb. 28), with $21.2 million cash on hand...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.